Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
• Understudied Native Hawaiian and Pacific Islander populations in Alzheimer's Disease and Related Dementia. • Risk and resiliency factors in Alzheimer's Disease and Related Dementia for American Samoa adults. • Using the Kimberley Indigenous Cognitive Assessment tool to determine ADRD potentially modifiable risk and protective factors.
Why it matters
This study aims to characterize risk and protective factors for Alzheimer's disease and related dementias in American Samoa, an understudied population, using the Kimberley Indigenous Cognitive Assessment tool. No results on treating, curing, or preventing dementia are reported.
-
Evaluate the performance of emerging Alzheimer disease (AD) plasma biomarkers in a specialty memory clinic.
Why it matters
This entry only states the aim of evaluating how emerging Alzheimer's blood biomarkers perform in a specialty memory clinic. No results or conclusions are provided in the available text, so nothing can be said about what it means for treating, curing or preventing the disease.
-
34/100
The median age of the participants was 69 years, with a median MMSE score of 16.
Why it matters
In this group of Alzheimer's patients in India, all experienced some pain and at least one behavioral or psychological symptom, and pain was significantly associated with these symptoms. This underscores the importance of assessing and managing pain to improve patient well-being, but it does not address curing or preventing dementia.
-
Early and accurate diagnosis of Alzheimer's disease (AD) will be key for effective personalized treatment plans ( Cummings, 2023).
Why it matters
In male amyloidosis mice, changes in the auditory brainstem response allowed a machine learning algorithm to detect disease when memory decline appeared. The authors note the findings come from amyloidosis mice and propose the measure be evaluated as a diagnostic biomarker, not a treatment.
-
NPS affects up to 80% of individuals with early AD or MCI, often preceding cognitive decline.
Why it matters
This review found that neuropsychiatric symptoms affect up to 80% of people with early Alzheimer's disease or mild cognitive impairment and often precede cognitive decline. Current management relies mainly on non-pharmacological interventions, and no new treatment or cure is tested.
-
SDOH are potentially modifiable factors, therefore, a deeper understanding of their effects on ADRD can inform future interventions aimed at reducing ADRD prevalence and disparities.
Why it matters
This study found that age-adjusted Alzheimer's disease and related dementias prevalence was 15.6% among American Indian and Alaska Native Medicare beneficiaries versus 13.4% among White beneficiaries, but the odds ratio for AI/AN was not statistically significant after multivariate adjustment. The work examines social determinants and prevalence, not treatment, cure, or prevention.
-
Technical developments have paved the way for the development of ultrasensitive analytical methods that allow for precise quantification of brain-specific proteins in blood samples.
Why it matters
This review describes blood biomarkers, noting that the plasma amyloid beta 42/40 ratio overlaps too much with normal elderly for reliable clinical use, while plasma p-tau217 is markedly increased in early symptomatic Alzheimer's disease and normal in other neurodegenerative disorders. It concerns diagnosis and does not report any treatment, cure, or prevention.
-
Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval.
Why it matters
This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and donanemab—which are the first disease-modifying treatments for Alzheimer disease to receive FDA approval or be pending it. It discusses their clinical efficacy, dosing, side effects and practical issues with using them as common treatments to slow decline.
-
Autoantibody-associated psychiatric syndromes are a novel disease entity that is not fully understood.
Why it matters
This retrospective study compared cerebrospinal fluid neurodegeneration markers between psychiatric patients with and without neural autoantibodies. It concerns a different condition and does not report any treatment, cure, or prevention for Alzheimer's disease.
-
This review addresses recent developments in the analyses of plasma amyloid beta (Aβ) and total tau (t-tau) protein levels as biomarkers for discriminating amnestic mild cognitive impairment (aMCI) from Alzheimer disease (AD), using immunomagnetic reduction (IMR).
Why it matters
This review of 15 clinical studies found that a blood test method detected lower amyloid beta 1-40 and higher amyloid beta 1-42 and total tau in people with amnestic mild cognitive impairment and Alzheimer's disease. It concerns diagnosis only and does not offer a treatment.
-
In the last 15 years, huge efforts against Alzheimer's disease (AD) with drugs targeting β-amyloid (Aβ) and tau have produced poor clinical results.
Why it matters
This review of past Alzheimer's drug trials found that 15 years of efforts targeting β-amyloid and tau produced poor clinical results. The authors state that aducanumab, an anti-Aβ antibody, has been met with distrust by most experts, hospitals and insurance companies because of its level of efficacy and poor tolerability.
-
The 2018 NIA-AA research framework proposes a classification system with beta- A myloid deposition, pathologic T au, and n eurodegeneration (ATN) for the diagnosis and staging of Alzheimer’s Disease (AD).
Why it matters
Using baseline cerebrospinal fluid peptides and MRI data from 287 people followed for 3 to 10 years, this study identified a cut-point based signature for predicting Alzheimer's disease progression that supports the 2018 NIA-AA research framework. It is a prediction and staging tool, not a treatment, cure, or prevention.
-
34/100
Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI.
Why it matters
This review states that amyloid PET and cerebrospinal fluid measures of amyloid-beta, total-tau and phospho-tau are clinically available to support a diagnosis of Alzheimer disease or mild cognitive impairment due to it. It advises using biomarker testing when there is diagnostic uncertainty and the result would affect diagnosis or treatment.
-
Patients with AD display signs and symptoms of functional impairment from early stages.
Why it matters
In 11-month-old female 3xTg-AD mice, motor and cellular changes in the primary motor cortex were linked to amyloid-beta and hyperphosphorylated tau deposition. This is an animal-model study and does not show any treatment, cure or prevention for people.
-
Alzheimer's disease (AD) is neuropathologically characterized by neuritic plaques and neurofibrillary tangles.
Why it matters
This study found that both plaques and tangles were more prominent in sulcal fundi than gyri crowns across seven cortical areas in Alzheimer's disease brains. It is a descriptive pathology study and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Vascular risk factors (e.g. hypertension, dyslipidemia and diabetes) are well known risk factors for Alzheimer' disease.
Why it matters
This review discusses how vascular risk factors such as hypertension, dyslipidemia, and diabetes relate to amyloid burden and brain integrity, and notes that vascular brain injuries and amyloid appear to affect the brain independently and additively. It stresses monitoring vascular risk factors in midlife as a prevention strategy, but presents no new trial results.
-
The potential of brain imaging has grown rapidly with new modalities, hybrid combinations of existing modalities, and novel metabolic tracers.
Why it matters
This report describes two patients in whom PET/MRI combined with F-florbetapir was used to help tell different dementias apart. It is a small two-case report, so it does not show whether this imaging approach changes treatment, cure, or prevention of Alzheimer's disease.
-
The goals of this study were to compare the early diagnostic utility of Alzheimer disease biomarkers in the CSF with those in brain MRI in conditions found in our clinical practice, and to ascertain the diagnostic accuracy of both techniques used together.
Why it matters
In 30 people with mild cognitive impairment, this study compared brain MRI and cerebrospinal fluid biomarkers for early diagnosis and followed them for two years. It is a small study about diagnostic testing, not about treating, curing or preventing Alzheimer's disease.
-
The BACE1 gene encodes the beta-site APP-cleaving enzyme 1 and has been associated with Alzheimer's disease (AD).
Why it matters
This study found that BACE1 gene variants did not influence BACE1 activity, APP levels or amyloid beta isoforms in cerebrospinal fluid in Alzheimer's disease. It is a negative genetic finding about the amyloid pathway, not about treating, curing or preventing the disease.
-
The evidence to support a claim that a new drug will slow the progression of Alzheimer disease (AD) must derive from epistemologically valid research methods.
Why it matters
This is a methods paper about how to design and evaluate trials that claim to slow Alzheimer's disease progression. It does not test any treatment and provides no evidence for curing or preventing the disease.
-
We quantified the synaptic density in the outer molecular layer of the hippocampal dentate gyrus.
Why it matters
In brain tissue examined after death from 9 people with Alzheimer's disease and 10 age-matched people without dementia, electron microscopy found fewer synapses in the outer molecular layer of the hippocampal dentate gyrus, and the whole molecular layer was thinner. Where synapses were fewer, the remaining contacts were longer. The authors suggest this loss of connections "could play a key role in memory-related problems," but the study did not measure memory and does not test any treatment or prevention.
-
A comprehensive baseline of emotional functioning was established for adults with Down syndrome.
Why it matters
This study compared emotional factors in adults with Down syndrome, people with Alzheimer-type dementia, and elderly controls, finding indifference, pragnosia and inappropriateness as distinguishing factors. It concerns emotional signs that may signal dementia, not any treatment, cure or prevention.
-
Peripheral auditory status was statistically similar between subject groups.
Why it matters
People in early to middle phases of Alzheimer's disease showed impaired central auditory processing compared with nondemented elderly, though peripheral auditory status was similar. The results support screening for central auditory dysfunction in this population but do not indicate a treatment, cure, or prevention for Alzheimer's disease.
-
We previously observed low level mosaicism (2-4% normal cells) in phytohemagglutinin-stimulated peripheral blood lymphocytes (PBL) in 29% of a small group of elderly persons with Down syndrome (DS).
Why it matters
This analysis of cytogenetic data found that the proportion of diploid cells increased with age in people with trisomy 21, suggesting loss of a chromosome 21 over time. The authors propose this might be relevant to Alzheimer-type dementia, but this is a hypothesis and no treatment or prevention is tested.
-
The cause(s) of Alzheimer disease (AD) remain unknown.
Why it matters
This study found brain reactive antibodies in 57% of people with Alzheimer disease, 81% of older people with Down syndrome, and 30% of normal controls, but the pattern of reactivity differed between the two conditions. It is a laboratory blood study and does not show a treatment or cure.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- A common 19 bp APOE enhancer deletion is protective against Alzheimer's disease in African Americans
- The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
- Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives
- Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline
- Preliminary investigation of obstructive sleep apnea and Alzheimer's disease in down syndrome
- Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer's disease
- Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum
- Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review
- Genetic Architecture of Plasma Amyloid and Tau Biomarkers in the Amish
- Alzheimer's disease